# John Li

> John Li, also identified in Chinese company materials as 李月华, is a scientist and company founder who established Salubris Biotherapeutics in 2016 and served as its founding president and CEO. A graduate of Fudan University and North Carolina State University, he previously held scientific leadership roles at Tanox, GSK and MedImmune. Recent conference material identifies him as founder and CEO of Latticon.

- **Role:** Founder & CEO at Latticon Antibody Therapeutics, Inc.
- **Organizations:** Salubris Biotherapeutics, Inc., Latticon Antibody Therapeutics, Inc., Latticon (Suzhou) Biopharmaceuticals Co., Ltd., Shenzhen Salubris Pharmaceuticals, MedImmune / AstraZeneca, GlaxoSmithKline, Tanox / Genentech
- **Education:** B.S. in Biochemistry, Fudan University, Ph.D., North Carolina State University
- **Known for:** Founded Salubris Biotherapeutics and served as its founding president and CEO., Helped establish SalubrisBio’s Maryland operation, which held its formal opening in May 2017., Named inventor on multiple US patents.

## Career timeline

- **Before 2016** — Held scientific leadership roles at Tanox, GlaxoSmithKline and MedImmune.
- **2016** — Joined the Salubris research organization; founded Salubris Biotherapeutics, incorporated in Delaware on August 11.
- **2016-10** — Agreed to transfer 100% of SalubrisBio shares to the Salubris group subsidiary Chengdu Jinkai for $1 following preliminary company preparations.
- **2017-05** — Hosted the May 1 opening ceremony of SalubrisBio’s laboratory in Gaithersburg as founding president and CEO.
- **2020-11** — Latticon’s Suzhou company was established; a 2023 interview gives the incorporation date as November 6, 2020.
- **2023-01** — Listed as CEO presenting Latticon Antibody Therapeutics at Biotech Showcase; that US company listing gives 2021 as its establishment year.
- **2023-05** — Latticon obtained approval for RMB 10 million of research-asset-backed bank credit, with RMB 5 million initially disbursed.
- **2026** — Identified as Latticon founder and CEO in bioSeedin conference coverage.

## Achievements

- Founded Salubris Biotherapeutics and served as its founding president and CEO.
- Helped establish SalubrisBio’s Maryland operation, which held its formal opening in May 2017.
- Named inventor on multiple US patents.
- Led Latticon during a 2023 financing arrangement using research-pipeline assets as loan collateral.

## Latest updates

- **2026-10** — bioSeedin conference coverage identifies John Li as founder and CEO of Latticon Antibody Therapeutics.
- **2026-07** — A July 28 conference report identifies 李月华 as Latticon chairman and includes an event photograph.

## Links

- LinkedIn: https://www.linkedin.com/in/john-li-5ba00a45/

---

Profile page: https://yespress.io/john-li
Published by YesPress — https://yespress.io
Last updated: 2026-10-22